Kalbe Farma Reports Unaudited Earnings Results for the First Half of 2016; Maintains Earnings Guidance for the Year 2016
August 01, 2016 at 10:14 am EDT
Share
Kalbe Farma reported unaudited earnings results for the first half of 2016. The company reported a 9.6% year-on-year (y/y) rise in net sales to IDR 9.6 trillion (USD 736 million), boosted by Indonesia's economic recovery and improving purchasing power. The company's operating income grew 10.1% y/y while net profit rose 7.8% y/y to IDR 1.1 trillion.
The company maintained its full-year sales target of 8-10% net growth, along with the same forecast for net profit. The company also plans to allocate capital expenditure of IDR 1.0-1.5 trillion, mainly for expanding production and distribution capacity.
PT Kalbe Farma Tbk is an Indonesia-based company, which is engaged in the development, manufacturing and trading of pharmaceutical products including human medicines and consumer health products. Its business divisions include Prescription Pharmaceutical, Consumer Health Division, Nutritionals, and Distribution and Logistic divisions. The Prescription Pharmaceuticals division provides a range of products for all groups, from unbranded generic drugs for the mass-market segment, to branded generics and licensed drugs. The Consumer Health division's product portfolio spans from over the counter (OTC) drugs and energy drinks to a selection of ready-to-drink healthy beverage products. The Nutritional division manages a range of nutritional products, comprising of powdered milk products for all age segments. It also offers a selection of non-milk nutritional products. The Distribution and Logistics Division operates the distribution coverage for pharmaceuticals products in Indonesia.
PT KALBE FARMA TBK. 
